Next |
home / stock / abos / abos message board
Subject | By | Source | When |
---|---|---|---|
Down over 50% from yearly highs and still | Moonboy1 | investorshub | 12/02/2022 11:21:07 AM |
One penny away haha. That's amazing. Charts never lie. | Moonboy1 | investorshub | 10/27/2022 10:29:02 PM |
Almost there. | Moonboy1 | investorshub | 10/26/2022 1:27:44 AM |
Getting close to my buy price. 6s probably today | Moonboy1 | investorshub | 10/21/2022 12:16:26 PM |
I'm a buyer under $7. Just going by | Moonboy1 | investorshub | 10/19/2022 1:43:05 PM |
I never look at YouTube or analysts ELLIOTT | starkd748 | investorshub | 10/13/2022 7:12:27 PM |
I know TA. I was just pointing out | Moonboy1 | investorshub | 10/13/2022 12:17:59 PM |
I know TA. I was just pointing out | Moonboy1 | investorshub | 10/13/2022 12:16:52 PM |
7.95 at the .618 is a buy if | starkd748 | investorshub | 10/13/2022 5:15:05 AM |
So how much did they pay these analysts | Moonboy1 | investorshub | 10/11/2022 2:57:03 AM |
Closed @ $10 :) | subslover | investorshub | 10/05/2022 12:42:47 AM |
Me too I'm waiting next week lol | starkd748 | investorshub | 10/01/2022 12:41:51 AM |
Where's the gap? I can't get my bar | Moonboy1 | investorshub | 09/30/2022 8:23:48 PM |
I would like the share price to get | Imott | investorshub | 09/30/2022 5:05:32 PM |
Gap fill time stochastic overbought | starkd748 | investorshub | 09/30/2022 2:04:57 PM |
Yes! | subslover | investorshub | 09/30/2022 5:57:35 AM |
broke to the UPside nicely today | TheFinalCD | investorshub | 09/30/2022 1:53:59 AM |
Waiting on the gap to fill then I | starkd748 | investorshub | 09/29/2022 9:14:28 AM |
the open shook some out, then it took | TheFinalCD | investorshub | 09/29/2022 4:50:37 AM |
Pick me up 9 | Pt3 | investorshub | 09/28/2022 4:00:49 PM |
News, Short Squeeze, Breakout and More Instantly...
Acumen Pharmaceuticals Inc. Company Name:
ABOS Stock Symbol:
NASDAQ Market:
Acumen Pharmaceuticals Inc. Website:
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024 Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024 Cash, cash equivalent...
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that...
CHARLOTTESVILLE, Va., May 08, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that...